These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19558562)

  • 1. In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis.
    Goel A; Mittal A; Evstatiev R; Nemeth M; Kruis W; Stolte M; Boland CR; Gasche C
    Aliment Pharmacol Ther; 2009 Sep; 30(6):634-42. PubMed ID: 19558562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity and polymorphism of Bethesda panel markers in Chinese population.
    Zheng Y; Chen J; Zhang X; Xie L; Zhang Y; Sun Y
    Bull Cancer; 2020 Nov; 107(11):1091-1097. PubMed ID: 32980144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
    Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
    Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
    Støa-Birketvedt G; Florholmen J
    Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
    Henker J; Müller S; Laass MW; Schreiner A; Schulze J
    Z Gastroenterol; 2008 Sep; 46(9):874-5. PubMed ID: 18810672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
    Harris MS; Lichtenstein GR
    Aliment Pharmacol Ther; 2011 May; 33(9):996-1009. PubMed ID: 21385194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
    Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
    Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
    Adam B; Liebregts T; Holtmann G
    Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
    [No Abstract]   [Full Text] [Related]  

  • 9. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
    Kruis W; Fric P; Pokrotnieks J; Lukás M; Fixa B; Kascák M; Kamm MA; Weismueller J; Beglinger C; Stolte M; Wolff C; Schulze J
    Gut; 2004 Nov; 53(11):1617-23. PubMed ID: 15479682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenomatous Polyposis Coli, mismatch repair, and microsatellite instability in colorectal cancer based on different locations.
    Effendi-Y S R; Zain LH; Siregar GA; Lubis HR; Damanik HA; Laksmi LI; Chrestella J
    Acta Med Indones; 2013 Oct; 45(4):275-83. PubMed ID: 24448331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial.
    Vernia P; Annese V; Bresci G; d'Albasio G; D'Incà R; Giaccari S; Ingrosso M; Mansi C; Riegler G; Valpiani D; Caprilli R;
    Eur J Clin Invest; 2003 Mar; 33(3):244-8. PubMed ID: 12641543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.
    Matthis AL; Zhang B; Denson LA; Yacyshyn BR; Aihara E; Montrose MH
    Inflamm Bowel Dis; 2016 Aug; 22(8):1793-802. PubMed ID: 27416043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study.
    Pontes C; Vives R; Torres F; Panés J
    Inflamm Bowel Dis; 2014 Nov; 20(11):2004-12. PubMed ID: 25192498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
    Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
    Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
    Kruis W; Schütz E; Fric P; Fixa B; Judmaier G; Stolte M
    Aliment Pharmacol Ther; 1997 Oct; 11(5):853-8. PubMed ID: 9354192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite Instability in Mouse Models of Colorectal Cancer.
    Currey N; Daniel JJ; Mladenova DN; Dahlstrom JE; Kohonen-Corish MRJ
    Can J Gastroenterol Hepatol; 2018; 2018():6152928. PubMed ID: 29686976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
    Kruis W; Schreiber S; Theuer D; Brandes JW; Schütz E; Howaldt S; Krakamp B; Hämling J; Mönnikes H; Koop I; Stolte M; Pallant D; Ewald U
    Gut; 2001 Dec; 49(6):783-9. PubMed ID: 11709512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of aminosalicylates in the treatment of ulcerative colitis.
    Van Assche G; Baert F; De Reuck M; De Vos M; De Wit O; Hoang P; Louis E; Mana F; Pelckmans P; Rutgeerts P; Van Gossum A; D'Haens G
    Acta Gastroenterol Belg; 2002; 65(4):196-9. PubMed ID: 12619425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
    Karamanolis DG; Papatheodoridis GV; Xourgias V
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1083-8. PubMed ID: 8944370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis.
    Tahara T; Inoue N; Hisamatsu T; Kashiwagi K; Takaishi H; Kanai T; Watanabe M; Ishii H; Hibi T
    J Gastroenterol Hepatol; 2005 May; 20(5):710-5. PubMed ID: 15853983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.